Health policy: Putting a price on cancer

Nature Reviews Clinical Oncology

Volumn 13, Issue 3, 2016, Pages 137-138

  Sullivan, Richard ^a   Aggarwal, Ajay ^a,b  

^a GUY S HOSPITAL   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BLADDER CANCER; BUDGET; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURGERY; CHILDHOOD CANCER; DRUG COST; EARLY DIAGNOSIS; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MEDICAL DECISION MAKING; MOLECULARLY TARGETED THERAPY; OUTCOME ASSESSMENT; PATIENT CARE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTON THERAPY; ROBOT ASSISTED SURGERY; SHORT SURVEY; SOCIOECONOMICS; SUSTAINABLE DEVELOPMENT; COST BENEFIT ANALYSIS; COST CONTROL; ECONOMICS; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; HEALTH CARE POLICY; LEGISLATION AND JURISPRUDENCE; MORTALITY; NEOPLASMS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; COST SAVINGS; COST-BENEFIT ANALYSIS; DRUG COSTS; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HUMANS; NEOPLASMS; TREATMENT OUTCOME;

EID: 84959143151     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2016.12     Document Type: Short Survey

References (12)

1. Kantarjian, H. M., Fojo, T., Mathisen, M. & Zwelling, L. A. Cancer drugs in the United States: justum pretium - the just price. J. Clin. Oncol. 31, 3600-3604 (2013).
2. Vogler, S., Vitry, A. & Babar, Z.-U.-D. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. Lancet Oncol. 17, 39-47 (2016).
3. Light, D. W. & Lexchin, J. Foreign free riders and the high price of US medicines. BMJ 331, 958-960 (2005).
4. Leal, J., Luengo-Fernandez, R., Sullivan, R. & Witjes, J. A. Economic burden of bladder cancer across European Union. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2015.10.024 (2015).
5. Luengo-Fernandez, R., Leal, J., Gray, A. & Sullivan, R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 14, 1165-1174 (2013).
6. Marmot, M. Achieving health equity: from root causes to fair outcomes. Lancet 370, 1153-1163 (2007).
7. Davis, C. Drugs, cancer and end-of-life care: a case study of pharmaceuticalization? Soc. Sci. Med. 131, 207-214 (2015).
8. Cherny, N. I. et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann. Oncol. 26, 1547-1573 (2015).
9. Fojo, T., Mailankody, S. & Lo, A. Unintended consequences of expensive cancer therapeutics-the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. JAMA Otolaryngol. Head Neck Surg. 140, 1225-1236 (2014).
10. Persson, U. & Jonsson, B. The end of the international reference pricing system? Appl. Health Econ. Health Policy http://dx.doi.org/10.1007/s40258-015-0182-5(2015).
11. Chalkidou, K. et al. Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries. Lancet Oncol. 15, e119-e131 (2014).
12. Jamison, D. T. et al. Global health 2035: a world converging within a generation. Lancet 382, 1898-1955 (2013).